Method for producing a defective interfering viral genome (DVG), defective interfering particles comprising the DVG, and methods and uses thereof.

A peptide comprising the rhinovirus immunogen peptide of the rhinovirus structural protein 1 (VP1) of rhinovirus C and related vaccines and therapeutic compositions is disclosed.

The present invention relates to Human Rhinovirus (HRV) Virus-Like Particles (VLPs) and methods of making HRV VLPs.

Novel compositions useful as human rhinovirus immunogens are provided. The compositions enable a host response to sites normally not recognized by a host.

HRV VP2 proteins useful as components of immunogenic compositions for the induction of cross-reactive cell-mediated immunity against human rhinovirus infection; nucleic acid constructs encoding such HRV VP2 proteins.

Novel compositions useful as human rhinovirus immunogens are provided. The compositions enable a host response to sites normally not recognized by a host.

The present invention relates to methods, compositions and kits for the treatment or prevention of respiratory conditions. In particular, the methods, compositions and kits are particularly useful, but not limited to, the prevention and/or treatment of rhinovirus infection and the prevention and/or treatment of asthma exacerbation. The invention provides a method inhibiting a rhinovirus infection in a subject comprising administering a composition consisting of a compound comprising a TLR2 agonist and a pharmaceutically acceptable carrier.

Fusion proteins comprising a carrier protein and a Human Rhinovirus (HRV) peptide, and immunogenic compositions containing such fusion proteins.

A peptide comprising the rhinovirus immunogen peptide of the rhinovirus structural protein 1 (VP1) of rhinovirus C and related vaccines and therapeutic compositions is disclosed.

An analysis of human CD4.sup.+ T-cell epitopes of RV capsid proteins with cross-reactive potential was performed, peptide epitopes of RV-A16 capsid proteins VP1 and VP2 were identified, RV-specific CD4.sup.+ T cells were phenotyped for surface markers and cytokine profiles using flow cytometry, and it was found that, among non-infected subjects, circulating RV-A16-specific CD4.sup.+ T cells detected at the highest frequencies targeted 10 unique epitopes with diverse HLA-DR binding capacity. T-cell epitopes localized to conserved regions of significance to the virus and were enriched for HLA class I and II binding motifs and were activated in vivo after experimental infection with RV-A16. RV-A16 epitopes constituted species-specific and pan-species varieties, together providing 90% coverage of the US population. Cross-reactivity was evidenced for RV-A16 and RV-A39. High-frequency circulating RV-specific memory Th1 cells in healthy individuals preferentially target a limited set of conserved epitopes and these epitopes, separately or combined, can serve as vaccines.